Global Malaria Burden

  • 228,000,000 cases of malaria annually

  • 405,000 deaths per year​​​​

                                                         

 - World Health Organization (WHO)

pointing at globe

Current Diagnostics

  • Current gold standard testing, including rapid diagnostic tests and microscopy, can miss malaria cases.

  • This is particularly a problem in patients that have low levels of malaria parasite at the time of the test or when diagnosing pregnant women.​

  • Patients that have been misdiagnosed, or do not show symptoms act as a reservoir for future malaria transmission.

  • Current ultra-sensitive diagnostics on the market are not designed to be robust enough for deployment in rural Africa and other malaria-endemic regions.

The Illucidx Malaria Dx Solution

Illucidx team members from the University of Calgary have collaborated with partners in Ethiopia to advance malaria diagnostics for years.

  • We have seen firsthand what is feasible and what is not when deploying diagnostics in remote malaria-endemic regions of the world.

  • The solution we are developing is 100 to 1000 times more sensitive than the current field-deployed diagnostics.

  • It is specifically designed to be robust and simple to use with minimal training and laboratory infrastructure; dedicated laboratory space and consistent electricity will not be required.

  • Our test is shelf-stable, allowing it to be brought to point-of-care with detection levels comparable to those of laboratory-based tests.

  • Cost that is economical and practical for large scale deployment in low and middle-income countries.

  • We are currently perfecting moving our diagnostic chemistry to a cartridge-based system.